Move over Botox Cosmetic, Dysport and Xeomin. There’s a new neurotoxin in town and it’s anticipated to be available in doctor’s offices by the end of 2018.
Known as Nabota and manufactured by the Korean company, Daewoong Pharmaceutical, the new neurotoxin will be distributed stateside by Alphaeon. Nabota is currently in the FDA-approval process for the treatment of frown lines in adults.
You May Also Like: Happy Birthday, Botox! 8 Fascinating Facts About the Injectable That Changed the Beauty Industry
“Submission of the BLA within three years of the first study enrollment speaks of our experience, drive and commitment. We are excited to move one step closer to its commercial launch,” Chris Marmo, president of Beauty for Alphaeon, said in a press release.
“This is a very exciting development for plastic surgeons and dermatologists. Botox is, and has been for a long time, the king of cosmetic treatments—for good reason, too!,” says Troy, MI, plastic surgeon Anthony Youn, MD. “Although at this time we don’t know how Alphaeon’s new botulinum toxin stacks up against Botox, any competition in this market is a good thing. I’m excited to try it when it comes out.”
